Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | PAK4 | O96013 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | LTK | P29376 | 1/20 | 0.39 |
| ▸ | GRK5 | P34947 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019091 | 0.86 | HCAR2 (0.55) | F2HCAR2ADORA3TSHRMC4R | |
| SCHEMBL25198285 | 0.85 | NNMT (0.35) | F2GSK3BKDRCHEK1AURKA | |
| SCHEMBL5875664 | 0.85 | RAB9A (0.47) | F2GSK3BCDK5HCAR2TSHR | |
| SCHEMBL5875608 | 0.81 | HCAR2 (0.37) | F2GSK3BKDRCHEK1AURKA | |
| SCHEMBL27695580 | 0.81 | ADORA3 (0.34) | F2GSK3BKDRCHEK1AURKA | |
| SCHEMBL2230408 | 0.80 | HDAC6 (0.53) | F2SMN1; SMN2 | |
| SCHEMBL2203055 | 0.80 | HDAC6 (0.49) | F2GSK3BKDRCHEK1AURKA | |
| SCHEMBL25200247 | 0.80 | GSK3B (0.43) | F2GSK3BKDRCHEK1AURKA | |
| SCHEMBL5196234 | 0.80 | FFAR2 (0.40) | KDRHCAR2FFAR2TSHRHRH3 | |
| SCHEMBL1238343 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4214210-B1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | NOVARTIS AG (CH) | 2025-04-09 | — | — | EP | claimed |
| CN-116615425-A | Compounds and compositions as Sppl2a inhibitors | 诺华股份有限公司 | 2023-08-18 | — | — | CN | claimed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | claimed |
| EP-4214210-B1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | NOVARTIS AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| CN-116615425-A | Compounds and compositions as Sppl2a inhibitors | 诺华股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | F2 3094/4885GSK3B 1242/4885KDR 2519/4885 |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | F2 3094/4885GSK3B 1242/4885KDR 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.